Q-omics provides the consensus-scored CCDC91 profile across patient tissues and cancer cell-line models. CCDC91 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CCDC91 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, CCDC91 protein abundance shows 20,938 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight LIHC, HNSC, and UCEC as cancer lineages where CCDC91 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC91 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC91 survival associations across molecular data types. CCDC91 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC91 RNA expression–survival associations across cancer types. High CCDC91 expression shows unfavorable associations in LIHC, LGG, SCLC, LUSC and KICH, but favorable associations in PRAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CCDC91 RNA expression.
This table summarizes CCDC91 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CCDC91. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC91 shows lower tumor expression in THCA and UCEC and higher tumor expression in HNSC, LIHC, CHOL and LUSC. The HNSC box plot shows higher CCDC91 RNA expression in tumor versus normal tissue (log2 FC = +0.943, t-test p < 0.001).
This table shows molecular features associated with CCDC91 in patient tissues and cancer cell lines. In patient samples, CCDC91 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC91 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Lymphoma.
